Chongqing Jianqiao Sues HolleyPharm Again For Patent Infringement
This article was originally published in PharmAsia News
Executive Summary
Chongqing Jianqiao Pharmaceutical Development has again sued Holley Pharmaceuticals, alleging that the latter's Duo-Cotecxin (dihyhroartermisinin piperaquine) tablets infringe on its patented compound for piperaquine tablets. Chongqing Jianqiao demands that HolleyPharm stop production and sale of the product, pay RMB 1 for economic losses, as well as issue a public apology and pay for court expenses. HolleyPharm claims thatDuo-Cotecxin's components are totally different from those of Chongqing Jianqiao's piperaquine tablets and it will be fighting the suit. Meanwhile, HolleyPharm has appealed its previous patent infringement case (PharmAsia News, Jul. 28, 2008). Analysts observe that an unfavourable ruling will negatively impact the firm as it will have to stop producing and selling Duo-Cotecxin locally if it loses the two cases. (Click here for more - Chinese Language)
You may also be interested in...
Holley Pharmaceuticals Loses Copyright Infringement Case
Chongqing Intermediate People's Court has declared Holley Pharmaceuticals (Chongqing) guilty of infringing on Chongqing Jianqiao Pharmaceutical Development's copyright. It ordered HolleyPharm to stop production of its Duo-Cotecxin (dihydroartemisinin) tablets immediately and destroy any drugs produced before the ruling, as well as pay Chongqing Jianqiao 1 yuan for economic losses. HolleyPharm has indicated it will appeal to Chongqing Higher People's Court but states that there will be little impact on its overseas drug production and sales even if the future ruling remains the same. According to the company, Duo-Cotecxin revenue in China makes up only 1 percent of its total income. (Click here for more - Chinese Language)
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.